A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program.
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 05 Sep 2012
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Novartis
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Nov 2011 Planned End Date changed from 1 Feb 2019 to 1 Jan 2019 as reported by ClinicalTrials.gov.
- 07 Sep 2011 Planned end date changed from 1 Dec 2018 to 1 Feb 2019 as reported by ClinicalTrials.gov.